Noetik vs Cardinal Health
Side-by-side comparison of AI visibility scores, market position, and capabilities
Noetik raised 2M and signed a 0M GSK licensing deal to build cancer biology foundation models on multi-omic data, uncovering drug targets invisible to conventional tools (2022, SF).
About
Noetik is a San Francisco-based AI-native biotechnology company founded in 2022 with the mission of decoding cancer biology at molecular resolution using foundation models trained on multi-omic data. The company was founded on the thesis that the biological complexity underlying cancer — the interactions between tumor cells, the immune system, the tumor microenvironment, and genomic variation — exceeds what human researchers or conventional computational tools can fully model, and that large-scale AI trained on comprehensive biological datasets can discover drug targets and patient stratification strategies that would otherwise remain hidden. Noetik builds cancer biology foundation models that learn the language of cellular systems from massive datasets of genomic, transcriptomic, and proteomic measurements.\n\nNoetik's platform applies its foundation models to drug discovery programs, with a focus on identifying novel targets in difficult-to-treat cancers and predicting which patient populations are most likely to respond to specific therapeutic mechanisms. The models are designed to generate hypotheses at a speed and scale that dramatically compresses the early discovery timeline, enabling the company and its partners to explore vastly more biological hypotheses per year than conventional approaches allow. Noetik's scientific platform is built to be partnered as well as proprietary — the company licenses its cancer biology AI capabilities to pharmaceutical companies seeking to accelerate and de-risk their early discovery pipelines.\n\nNoetik has raised $62 million in total funding and secured a $50 million licensing deal with GSK, one of the world's largest pharmaceutical companies, validating both the scientific quality of its foundation models and the commercial interest from major pharma in AI-native biology platforms. The GSK deal provides both capital and a prestigious scientific partnership that elevates Noetik's credibility across the drug discovery ecosystem. As AI biology becomes a defining competitive dimension in pharmaceutical R&D, Noetik's cancer-focused foundation models and demonstrated ability to attract top-tier pharma partnerships position it as an emerging leader in AI-driven oncology drug discovery.
Dublin OH pharmaceutical distribution (NYSE: CAH) $230B+ revenue; specialty pharma GLP-1 distribution tailwind, at-Home Solutions growth, medical divestiture to Medline competing with McKesson and Cencora.
About
Cardinal Health, Inc. is a Dublin, Ohio-based healthcare distribution and medical products company — publicly traded on the New York Stock Exchange (NYSE: CAH) as an S&P 500 Health Care component — distributing pharmaceutical products to pharmacies, hospitals, and healthcare providers, and manufacturing and distributing medical and surgical supplies through approximately 44,000 employees. In fiscal year 2025 (ending June 2025), Cardinal Health generated revenues exceeding $230 billion in its Pharmaceutical and Specialty Solutions segment — reflecting the company's role as a pass-through distributor of branded and generic pharmaceuticals at near-zero margin on drug cost, where Cardinal Health earns distribution fees and rebate income on enormous volumes. CEO Jason Hollar has executed a two-segment strategy focused on optimizing pharmaceutical distribution (Pharmaceutical and Specialty Solutions — $227B+ revenue at low margin) and growing medical products profitability (Global Medical Products and Distribution — higher-margin branded surgical products, Cardinal Health brand commodities, and at-Home Solutions). The 2024 divestiture of the medical segment's Cardinal Health Brand product line to Medline Industries for $1.1 billion simplified the medical segment focus toward specialty distribution and home healthcare supply. Cardinal Health's specialty pharmaceutical distribution (oncology, rheumatology, rare disease biologics through Cardinal Health Specialty Solutions) is a growing higher-margin subsegment as pharmaceutical manufacturers contract with specialty distributors for controlled dispensing of limited-distribution drugs.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.